These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 26478533)

  • 1. Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data.
    Stott LA; Hall DA; Holliday ND
    Biochem Pharmacol; 2016 Feb; 101():1-12. PubMed ID: 26478533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is biased efficacy? Defining the relationship between intrinsic efficacy and free energy coupling.
    Onaran HO; Rajagopal S; Costa T
    Trends Pharmacol Sci; 2014 Dec; 35(12):639-47. PubMed ID: 25448316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
    Luttrell LM; Maudsley S; Bohn LM
    Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G Protein-coupled Receptor Biased Agonism.
    Hodavance SY; Gareri C; Torok RD; Rockman HA
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):193-202. PubMed ID: 26751266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining efficacy: exploiting functional selectivity for drug discovery.
    Gesty-Palmer D; Luttrell LM
    Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging structural insights into biased GPCR signaling.
    Shukla AK; Singh G; Ghosh E
    Trends Biochem Sci; 2014 Dec; 39(12):594-602. PubMed ID: 25458114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When simple agonism is not enough: emerging modalities of GPCR ligands.
    Smith NJ; Bennett KA; Milligan G
    Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
    Wang CI; Lewis RJ
    Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A kinetic view of GPCR allostery and biased agonism.
    Lane JR; May LT; Parton RG; Sexton PM; Christopoulos A
    Nat Chem Biol; 2017 Aug; 13(9):929-937. PubMed ID: 28820879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.
    Bosier B; Hermans E
    Trends Pharmacol Sci; 2007 Aug; 28(8):438-46. PubMed ID: 17629964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of conformational ensembles of seven transmembrane receptors in functional selectivity.
    Vaidehi N; Kenakin T
    Curr Opin Pharmacol; 2010 Dec; 10(6):775-81. PubMed ID: 20933468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conceptual and experimental issues in biased agonism.
    Onaran HO; Costa T
    Cell Signal; 2021 Jun; 82():109955. PubMed ID: 33607257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An operational model for GPCR homodimers and its application in the analysis of biased signaling.
    Zhou B; Giraldo J
    Drug Discov Today; 2018 Sep; 23(9):1591-1595. PubMed ID: 29649573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical guide for calculating and representing biased signaling by GPCR ligands: A stepwise approach.
    Nagi K; Pineyro G
    Methods; 2016 Jan; 92():78-86. PubMed ID: 26364590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
    Luttrell LM
    Mol Endocrinol; 2014 Mar; 28(3):281-94. PubMed ID: 24433041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric coupling and biased agonism in G protein-coupled receptors.
    Bock A; Bermudez M
    FEBS J; 2021 Apr; 288(8):2513-2528. PubMed ID: 33621418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evasive nature of drug efficacy: implications for drug discovery.
    Galandrin S; Oligny-Longpré G; Bouvier M
    Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A conformation-equilibrium model captures ligand-ligand interactions and ligand-biased signalling by G-protein coupled receptors.
    Roth S; Bruggeman FJ
    FEBS J; 2014 Oct; 281(20):4659-71. PubMed ID: 25145284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window.
    Gillis A; Sreenivasan V; Christie MJ
    Mol Pharmacol; 2020 Oct; 98(4):410-424. PubMed ID: 32665252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.